Halozyme Therapeutics, Inc.
HALO
Xếp hạng trong cổ phiếu
#1550
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San... Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
Giá cổ phiếu
$123.66
Vốn hóa thị trường
$14.04B
Thay đổi (1 ngày)
-0.57%
Thay đổi (1 năm)
84.90%
Quốc gia
US
Giao dịch Halozyme Therapeutics, Inc. (HALO)
Danh mục
Healthcare
Số lượng cổ phiếu lưu hành của Halozyme Therapeutics, Inc. (HALO)
Số lượng cổ phiếu lưu hành vào ngày June 2026: 117.27M
Theo các báo cáo tài chính gần đây và giá cổ phiếu của Halozyme Therapeutics, Inc., số lượng cổ phiếu lưu hành hiện tại là 117.27M. Vào cuối December 2023, công ty có 131.93M cổ phiếu lưu hành. Số lượng cổ phiếu lưu hành thường bị ảnh hưởng bởi việc chia tách cổ phiếu và mua lại cổ phiếu.
Lịch sử cổ phiếu lưu hành của Halozyme Therapeutics, Inc. (HALO) từ 2001 đến 2026
Cổ phiếu lưu hành vào cuối mỗi năm
| Năm | Cổ phiếu lưu hành | Thay đổi |
|---|---|---|
| 2026 (TTM) | 117.27M | -7.53% |
| 2024 | 126.83M | -3.87% |
| 2023 | 131.93M | -3.59% |
| 2022 | 136.84M | -2.70% |
| 2021 | 140.65M | 3.26% |
| 2020 | 136.21M | -5.63% |
| 2019 | 144.33M | 0.62% |
| 2018 | 143.45M | 5.15% |
| 2017 | 136.42M | 7.26% |
| 2016 | 127.19M | 0.38% |
| 2015 | 126.70M | 3.27% |
| 2014 | 122.69M | 8.76% |
| 2013 | 112.81M | 1.56% |
| 2012 | 111.08M | 8.30% |
| 2011 | 102.57M | 8.70% |
| 2010 | 94.36M | 8.83% |
| 2009 | 86.70M | 8.59% |
| 2008 | 79.84M | 7.44% |
| 2007 | 74.32M | 18.70% |
| 2006 | 62.61M | 24.43% |
| 2005 | 50.32M | 42.09% |
| 2004 | 35.41M | 418.76% |
| 2003 | 6.83M | 48.41% |
| 2002 | 4.60M | 283.48% |
| 2001 | 1.20M | 0.00% |
Cổ phiếu lưu hành của các công ty tương tự hoặc đối thủ
| Công ty | Cổ phiếu lưu hành | Chênh lệch | Quốc gia |
|---|---|---|---|
| 253.90M | 116.50% |
US
|
|
| 396.00M | 237.67% |
US
|
|
| 478.91M | 308.37% |
AU
|
|
| 62.19M | -46.97% |
NL
|
|
| - | - |
CH
|
